Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT07570563
First seen May 13, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tests a new treatment called QH101 for people with blood cancers or solid tumors that have not responded to standard therapies. QH101 uses specially engineered immune cells from a donor to better recognize and kill cancer cells while lasting longer in the body. The trial will enroll 24 adults and focus on safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department of Chinsese PLA Gereral Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.